Pfizer, Inc. (PFE) Upgraded to “Buy” by ValuEngine
ValuEngine upgraded shares of Pfizer, Inc. (NYSE:PFE) from a hold rating to a buy rating in a research report sent to investors on Friday morning.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Pfizer from a hold rating to a buy rating and set a $40.00 target price on the stock in a report on Tuesday. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the stock a buy rating in a report on Tuesday, September 19th. Morgan Stanley upgraded shares of Pfizer from an equal weight rating to an overweight rating and raised their target price for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Vetr cut shares of Pfizer from a buy rating to a hold rating and set a $35.71 target price on the stock. in a report on Wednesday, September 13th. Finally, Jefferies Group LLC set a $37.00 target price on shares of Pfizer and gave the stock a neutral rating in a report on Monday, September 18th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $38.21.
Pfizer (PFE) traded up 0.14% during midday trading on Friday, reaching $36.05. 12,060,086 shares of the company’s stock were exchanged. The stock has a market cap of $214.40 billion, a PE ratio of 26.37 and a beta of 1.00. The firm has a 50 day moving average of $34.72 and a 200-day moving average of $33.69. Pfizer has a 12 month low of $29.83 and a 12 month high of $36.24.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share. On average, equities research analysts predict that Pfizer will post $2.56 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.55%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
In other news, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,521 shares of company stock worth $15,813,961. Company insiders own 0.06% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Altfest L J & Co. Inc. raised its position in shares of Pfizer by 67.0% in the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after purchasing an additional 43,024 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Pfizer in the 1st quarter worth about $13,342,000. Searle & CO. raised its position in shares of Pfizer by 92.7% in the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after purchasing an additional 38,500 shares during the last quarter. Insight 2811 Inc. raised its position in shares of Pfizer by 3.7% in the 1st quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock worth $319,000 after purchasing an additional 329 shares during the last quarter. Finally, Prentiss Smith & Co. Inc. raised its position in shares of Pfizer by 1.7% in the 1st quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock worth $511,000 after purchasing an additional 250 shares during the last quarter. 69.00% of the stock is owned by hedge funds and other institutional investors.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.